InMed Pharmaceuticals News | Press Releases

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Menu

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Press Releases

InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa

November 4, 2015

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000

November 2, 2015

InMed Appoints Paul Brennan as President & Chief Executive Officer

September 3, 2015

InMed Commences Development of Proprietary Drug Delivery System

September 2, 2015

InMed Appoints Paul Brennan to the Board of Directors

August 25, 2015

InMed Pharmaceuticals Announces Progress in Orofacial Pain Program

August 20, 2015

InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)

August 6, 2015

InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline

June 3, 2015

InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS)

May 26, 2015

InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases

May 12, 2015

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,232,750

May 7, 2015

InMed Engages Peter Mountford as Strategic Advisor

May 5, 2015

InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S.

April 30, 2015

InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy

April 15, 2015

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000

April 6, 2015

InMed Pharmaceuticals Strengthens Scientific Advisory Board

March 31, 2015

InMed Receives Exemption Status from Health Canada

March 23, 2015

InMed Pharmaceuticals added to CSE Composite Index

March 20, 2015

InMed Initiates Pre-clinical Work on Orofacial Pain

March 18, 2015

InMed Forms Strategic Collaboration to Develop Novel Phytocannabinoid Therapies for Ocular Allergies

March 10, 2015

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Next »

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

INM-901 for Alzheimer’s Disease
INM-089 for Age-related Macular Degeneration
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Novel Analogs

MANUFACTURING

BayMedica – Rare Cannabinoid Ingredients
Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM Materials
Filings
Presentations
Media & Videos
Investor Contact

CORPORATE

Management
Board of Directors
Scientific Advisors
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2024 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent*

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.

CAPTCHA